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Abstract
Objective To discuss the relationship between adipokines
and connective tissue diseases, by putting special emphasis
on the potential role of leptin, adiponectin, resistin, and
other adipose tissue products in the pathogenesis of rheu-
matoid arthritis and systemic lupus erythematosus and on
possible application of adipokine-targeted therapy in the
treatment of these disorders with emphasis on the recent
findings.
Methods PubMed literature search complemented by
review of bibliographies listed in identified articles.
Results Most of the data presented by different research
groups showed changed levels of leptin, adiponectin, and
resistin and occasionally also other adpokines in rheuma-
toid arthritis and systemic lupus erythematosus. The rela-
tionship between the remaining connective tissue diseases
and adipokines is less documented.
Conclusions Plasma levels of adipokines might tell us too
little about their role in connective tissue disorders,
whereas adipokine effects on synovial tissues might differ
from their known metabolic or cardiovascular effects,
which implies that some re-appraisal of adipokines role
may need to take place. It still remains obscure whether the
observed disturbances in various adipokine systems in
subjects with connective tissue diseases contribute to their
development or only reflect the presence or activity of
inflammatory process, which itself is induced by other pro-
inflammatory factors.
Keywords Adipose tissue  Adiponectin  Leptin 
Resistin  Rheumatoid arthritis  Systemic lupus
erythematosus
Introduction
Adipokines, proteins produced by the white adipose tissue
(WAT), have attracted the attention of scientists of various
specialties since 1994, when the first adipokine—leptin
was discovered. For decades, adipose tissue had been
regarded only as a storage depot for body energy,
mechanical defense against injuries, and a thermoregulator
[1]. The discovery of leptin, and a year later of adiponectin,
markedly broadened our knowledge on the contribution of
adipose tissue to whole-body homeostasis. Although, ini-
tially, adipokines were considered to determine their
association with eating disorders and diabetes, later studies
revealed that adipose tissue products play an important role
in the regulation of immune response and systemic
inflammatory processes. Taking into consideration their
action on inflammation, these peptides may be divided into
those inducing mainly pro-inflammatory [leptin, resistin,
interleukin (IL)-6, tumor necrosis factor a (TNF-a)]
or predominantly anti-inflammatory (adiponectin, IL-1
receptor antagonist, IL-10) effects [2].
The involvement of adipokines in the regulation of
inflammatory processes, in light of still obscure patho-
genesis of connective tissue diseases and insufficient con-
trol of these disorders by generally accepted medications,
aroused the interest of scientists in a possible causative role
of abnormal adipokine production in the pathogenesis of
autoimmune disorders and as potential targets for treatment
of these disorders. It was found that articular and extra-
articular changes associated with rheumatoid arthritis (RA)
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and reduced physical activity lead to the alteration in body
fat distribution, which include ‘‘cachectic obesity’’, a state
where muscle loss is accompanied by fat gain, so that in
early stages, body weight can remain stable [3]. Interest-
ingly, underweight or normal weight have been associated
with more active disease, while obesity has been accom-
panied by significantly less joint damage, both before and
during the treatment [4]. Also systemic lupus erythemato-
sus (SLE) pathogenesis may be related to body mass index
(BMI) status, which is confirmed by the fact that two-thirds
of patients suffering from this disease are overweight or
obese, either before or after diagnosis [5].
Physiological role of adipokines
Leptin
Leptin is a 16 kDa non-glycosylated polypeptide hormone
produced mainly by WAT, discovered by positional clon-
ing of a single gene mutation in the ob/ob mouse. In
humans, it is encoded by the Lep gene (an equivalent of the
ob gene in mouse) [6]. Circulating levels of leptin correlate
with BMI and the content of fat mass [7]. After crossing the
blood–brain barrier, leptin reaches the hypothalamus,
where it acts as a crucial regulator of feeding. Leptin is
mainly regarded as a ‘‘starvation-hormone’’ signaling from
the adipose tissue (AT) to the brain, indicating the size of
the AT-stores [8] and it exerts its action by inducing the
expression of anorexigenic factors and reducing the
hypothalamic production of orexigenic peptides. However,
leptin has been shown to influence a wide spectrum of
other biological functions [7–14] (Fig. 1). Its production
depends on the insulin levels, energy status, sex hormones,
and a wide range of inflammatory mediators, including
IL-1, TNFa, and leukemia inhibitory factor (LIF) [12, 15].
The fact that leptin synthesis and release is inhibited by
testosterone and stimulated by ovarian sex steroids
explains higher plasma leptin levels in women than in men,
even after adjustment for BMI [16].
Numerous studies showed increased plasma leptin levels
during infection and inflammation [17, 18], which is
probably secondary to the enhanced production of IL-1b,
TNFa, and IL-6. These data suggest that leptin plays a
relevant role in immunity as it affects the function of
immune cells by regulating cytokine production and
polarizing T helper cells toward Th1 [18].
Adiponectin
Adiponectin is a 244-amino acid protein, produced mainly
by WAT. The monomeric form (30 kDa) of adiponectin
seems to occur only in the adipocyte, whereas oligomeric
complexes circulate in plasma as low molecular weight
trimers (LMW), middle molecular weight hexamers
(MMW), and high molecular weight multimers (HMW)
[19]. There is also a globular form of adiponectin, which
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Fig. 1 Model of leptin action on hypothalamus and immune response
regulation (CART cocaine- and amphetamine-regulated transcript,
POMC proopimelanocortin, GLP-1 glucagon-like peptide-1, MSH
melanocyte-stimulating hormone, NPY neuropeptide Y, AGRP
agouti-related peptide, MCH melanin-concentrating hormone
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arises from the cleavage of full-length adiponectin by
leukocyte elastase [20]. Plasma adiponectin levels far
exceed plasma concentrations of other AT products [19].
A physiological significance of adiponectin has not yet
been fully explained. In opposition to most other adipocyte-
derived cytokines (leptin, resistin, adipsin, etc.), adiponec-
tin levels are decreased in obesity (probably through TNFa
and IL-6 downregulation). On the other hand, increased
adiponectin levels are observed in patients with anorexia
nervosa and in fasted healthy subjects [21]. It is generally
accepted that high adiponectin levels enhance insulin sen-
sitivity, while low adiponectin plasma levels are associated
with type 2 diabetes mellitus, dyslipidemia, and hyperten-
sion [22]. Thus, there is a negative correlation between low
adiponectin levels and severity of the metabolic syndrome
[23, 24].
In the majority of the studies conducted to date, adipo-
nectin produced anti-inflammatory effects (Fig. 2). Inter-
estingly, adiponectin inhibited TNFa and IL-6 production,
while both TNFa and IL-6 suppressed adipocyte adipo-
nectin production [2, 24], which suggests the existence of a
negative feedback between adiponectin and pro-inflam-
matory cytokines. TNFa- and IL-6-suppressing and the
remaining anti-inflammatory effects of adiponectin shown
in Fig. 2 [12, 25–27] may contribute to the protection
against CVD, which is lacking in obese subjects.
However, some reports surprisingly suggest pro-
inflammatory action of adiponectin [28, 29] (Fig. 2). It has
been evidenced that the serum concentration of adiponectin
is elevated in patients with classic chronic/autoimmune
inflammatory conditions, such as inflammatory bowel
disease or type 1 diabetes mellitus [24]. Although elevated
adiponectin levels could be explained by a compensatory
response of organism against inflammation, some
researchers find this explanation unconvincing and point to
the role of adiponectin in NFjB activation [28, 29].
This bidirectional, anti- and pro-inflammatory effects of
adiponectin may in part result from the changes in the rel-
ative proportion of its various isoforms. LMW adiponectin
has been shown to block endotoxin-induced secretion of
IL-6 and to induce IL-10 production, while MMW and
HMW adiponectin has been found to stimulate monocyte
chemoattractant protein-1(MCP-1) and IL-8 synthesis [30].
Interestingly, HMW adiponectin has been shown to serve
not only as a predictor of future cardiovascular events in
patients with coronary artery disease, but also as a marker
for severity of CAD [31], whereas the MMW/HMW ratio,
but not LMW or total adiponectin levels, correlated with the
incidence of myocardial infarction [32]. These findings
imply that measurement of adiponectin multimers adds
significant value in assessing cardiovascular risk compared
to total adiponectin alone and that the ratio of the isoforms
may determine adiponectin action.
Certainly, it cannot be excluded that adiponectin pro-
duction and secretion is regulated in a disease-dependent
manner and that adiponectin action depends on a type of
inflammatory disorder a patient suffers from.
Resistin
Resistin is a 12.5-kDa member of cysteine-rich proteins





























Fig. 2 Bidirectional properties of adiponectin
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zone’’ (FIZZ). It was initially described as an adipocyte-
derived protein and a mediator of hepatic insulin resistance
(IR) [33]. Interestingly, there are marked interspecies dif-
ferences in the source of production and structure of this
protein (Fig. 3). In mice, resistin is synthetized mainly by
WAT [34]. In humans, on the other hand, WAT produces
only small amounts of this protein [35], while relatively
high levels of resistin mRNA levels are detectable in cir-
culating mononuclear cells [36]. Physiological function of
resistin may in part differ between humans and rodents
[37], because of the fact that mouse and human resistin
share only about 64 % sequence homology at the mRNA
level and only 59 % identity at the amino acid structure
[38]. In humans, the best documented is its role in regu-
lating metabolic processes, adipogenesis, and inflammatory
reactions. Some [39, 40], but not other [41, 42], authors
found that plasma resistin levels positively correlate with
obesity and other constituents of the metabolic syndrome.
Moreover, high plasma resistin levels were found to cor-
relate with impaired renal function in patients with chronic
kidney disease [43], with the severity of inflammation in
inflammatory bowel disease [44], and with increased risk
for cardiac events in patients with congestive heart failure
[45] (Fig. 3).
The presence of FIZZ molecules within or near
inflammatory areas suggests the involvement of resistin in
the development of inflammatory responses. In humans,
resistin has a potency to induce the production of IL-6, IL-
1b, and TNFa by peripheral blood mononuclear cells
(PBMCs) [36, 46]. Also, synovial fluid cells express IL-6
and TNFa when stimulated by resistin. Similarly, pro-
inflammatory cytokines increase resistin expression in
PBMCs [47]. Bokarewa et al. [34] have demonstrated that
the pro-inflammatory effects of resistin are mediated
through the NF-jB signaling pathway.
Other adipokines
Recent years have witnessed the discovery of novel AT-
derived peptides.
Visfatin, an adipokine produced mainly by visceral
WAT, binds and activates the insulin receptor exerting its
insulin-mimetic effect. The structure of visfatin is identical
to pre-B-cell colony-enhancing factor (PBEF), the pro-
duction of which is increased in animal models of acute
lung injury and in neutrophils of septic patients [12, 21]. It
is also synthesized in endotoxin-stimulated neutrophils,
preventing apoptosis of these cells.
Vaspin is an adipose tissue–derived member of the serine
protease inhibitor family with insulin-sensitizing effects,
which seems to be a compensatory mediator for abrogating
obesity and its inflammatory complications [48].
Omentin, a peptide highly and selectively expressed in
visceral AT, is involved in the regulation of insulin action
[49]. Isolated from the omentum of patients with Crohn’s
disease, omentin is suggested to be implicated in the
pathogenesis of chronic inflammatory diseases [48].
Chemerin is a chemoattractant protein almost exclu-
sively expressed in adipose tissue and to much lesser extent
by immune-competent cells. It is implicated in metabolic
and immune homeostasis [50]. Its secretion in murine
adipocytes has recently been reported to be induced by
IL-1b [51].
Another novel adipokine, lipocalin 2 (LCN 2), is a
glycoprotein principally produced by WAT, but also iso-
lated from granules of neutrophils [52]. LCN2 induces
apoptosis in hematopoietic cells, modulates inflammation
and metabolic homeostasis [53]. It has recently been
identified in chondrocytes, where TNFa is a main regulator
of its expression.
Serum amyloid A3 (SAA3) belongs to the family of
acute-phase serum amyloid A proteins. In humans, SAA3
is a pseudogene and its functional protein is unknown. In
experimental studies, secretion of this adipokine is modu-
lated by IL-1b in adipocytes and chondrocytes [54], while
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adults [55]. It is characterized by symmetrical synovitis,
pannus formation, joint pain, stiffness, swelling, and
destruction. The presence of RA is associated with an
increased risk of the development of cardiovascular, neu-
rological, and metabolic disorders [56]. Although, in recent
years, the state of knowledge concerning the pathogenesis
of RA has dramatically increased, the detailed mechanisms
underlying this disease remain poorly understood, and
therefore, the factors responsible for the onset and pro-
gression of this disorder are the subject of intense research.
Undoubtedly, an important role is played by pro-inflam-
matory cytokines, particularly by TNFa, IL-1b, and IL-6
[55]. Taking into consideration the fact that articular and
synovial AT is an inseparable component of human joints,
local and systemic dysfunction in the synthesis, release,
and receptor action of adipocyte-derived proteins was the
aim of some recently published studies.
Leptin
It is assumed that Th1/Th2 imbalance plays an important
role in the development of RA with a postulated detri-
mental role of an increased Th1 response in this disorder
[57]. Leptin has been suggested to participate in modulat-
ing inflammation response through the induction of Th1
production of pro-inflammatory cytokines. Nevertheless, it
is still poorly investigated whether leptin directly induces
adipose tissue resident macrophages to release cytokines.
On the other hand, pro-inflammatory cytokines raise cir-
culating leptin levels, while in animal models leptin
enhances the release of IL-6, IL-12, and TNFa from peri-
toneal macrophages [13], and TNFa from synovium, which
suggests the existence of a local positive feedback between
cytokines and leptin in joint tissues [58].
Most of the experimental studies conducted to date
suggest a pro-inflammatory rather than protective action of
leptin in joint inflammatory disorders (Table 1). Several
studies confirm the protective impact of leptin deficiency
on antigen-induced arthritis and a stimulatory effect of
leptin on NO production [14, 58, 59]. Taking into consid-
eration a well-documented degenerative effect of NO on
joint cartilage, evoking the loss of chondrocyte phenotype,
inducing chondrocyte apoptosis, and increasing activation
of metalloproteases [60], an increase in leptin levels may
deteriorate joint inflammation via the local generation of
excessive amounts of NO. Surprisingly, the finding that the
administration of exogenous leptin elevates IGF-1 and
TGFb secretion by rat knee joint cartilage may suggest that
increased plasma leptin levels in obesity protect cartilage
against degeneration [12]. Treatment with leptin in animal
models of septic arthritis reduced the severity of joint
damage, which may indicate that leptin in the synovial
cavity exerts a protective effect against RA-induced joint
destruction [61]. Regrettably, the results of the latter study
were affected by a number of problems limiting their
interpretation, that is, cross-sectional character of the study,
which did not provide any information on the role of leptin
in the course of the disease; assessment of the disease
activity based only on plasma CRP levels; and lack of
information about the body mass index of the subjects
studied [62].
Despite generally consistent results of animal investi-
gations, suggesting pro-inflammatory implications of leptin
in the pathogenesis of RA, the data obtained from clinical
studies are not so unambiguous. There are several studies
that showed significantly elevated concentrations of leptin
in patients with RA [61, 63–66]. Otero et al. [55] observed
that plasma leptin levels increased markedly in patients
with RA, independently of BMI value, while Targonska-
Stepniak et al. [65] noted elevated leptin serum concen-
trations in patients with higher disease activity evaluated
by DAS 28, ESR, and the number of tender joints. Also,
Bokarewa et al. [66] reported elevated plasma leptin in RA,
though no adjustment for BMI was made in this study. It
was also noted that plasma concentrations of leptin were
significantly higher than synovial fluid leptin, and this
difference was particularly evident in non-erosive arthritis
[66].
Although the majority of studies revealed high systemic
and local leptin levels in patients and animals with RA,
some other studies did not support these results. Anders
et al. [67] found no differences between serum levels of
this adipokine in RA and healthy subjects. A fasting-
induced decrease in circulating leptin in RA patients was
associated with CD4? lymphocyte hyporeactivity and
increased IL-4 serum concentration [68]. Reduced serum
leptin levels in fasting RA patients resulted in a potentially
beneficial shift toward Th2 cytokine production [7],
increased insulin sensitivity, and rise in glucagon and
glucocorticoid synthesis [69].
A study by Popa et al. [70] demonstrated the existence
of an inverse correlation between severity of inflammation
and circulating leptin levels in active RA, suggesting
contribution of chronic inflammation to lowering plasma
leptin concentration. Striking is the fact that this study did
not reveal differences in leptinemia between the whole
group of RA patients and healthy controls, which was
explained by low inflammatory parameters at the time of
inquiry.
According to the aforementioned investigations [67, 68],
we may assume that improvements of symptoms may be
related to a significant decrease in plasma leptin levels due
to weight loss in the course of the disease. Nonetheless, it is
not obvious whether the increase of plasma leptin in RA is
just an effect of weight changes or it is rather a cause or a
consequence of pathology in RA.
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Adiponectin
The first report showing the existence of a correlation
between adiponectin and RA was published in 2003 by
Schaffler et al. [71]. The authors demonstrated that syno-
vial fluid concentrations of adiponectin were significantly
higher in patients with RA than in those with osteoarthritis
(OA). In 2004, Berner et al. [72] evidenced that adipo-
nectin is also expressed and secreted by osteoblasts, which
corroborated previous opinions about the role of adipo-
nectin in bone homeostasis. Elevation of synovial adipo-
nectin in RA was later confirmed by other studies [72, 73].
Ehling et al. [74] demonstrated a strong expression of
adiponectin mRNA in synovial fibroblasts and articular
adipocytes of RA and OA patients. The same study showed
that adiponectin induced, via p38 mitogen-activated pro-
tein kinase (MAPK) pathway, the synthesis of IL-6 and
pro-matrix metalloproteinase-1 (pro-MMP-1). What is
worth mentioning is that neutralization of TNFa activity by
etanercept and adalimumab resulted in a marked reduction
of IL-6 and pro-MMP-1. As the specific binding of enta-
nercept and adalimumab to adiponectin was excluded, pro-
inflammatory effects of adiponectin in the synovium were,
at least in part, mediated by TNFa [74]. As TNFa was
found to stimulate the p38 MAPK pathway, TNFa-directed
therapy may modulate adiponectin action on the level of
this signaling pathway [75].
Also, in other studies, adiponectin stimulated IL-6 pro-
duction [29] and, in opposition to leptin and resistin,
induced IL-8 expression [76] in rheumatoid synovial
fibroblasts and chondrocytes [77] (Table 1). At the level of
chondrocytes, adiponectin was found to exert pro-inflam-
matory effects by inducing the expression of inducible NO
synthase and by stimulating the release of IL-6, MMP-3,
MMP-9, and MCP-1 [78]. Another study reported that the
mean levels of adiponectin and type 1 adiponectin receptor
were higher in the synovial fluid of RA compared with OA
patients. Interestingly, there were no statistically significant
differences in serum adiponectin and the type 1 adiponectin
receptor content between RA, OA, or healthy control
subjects [79], while in endothelial cells adiponectin
reduced the expression of TNFa-induced IL-8 [80]. Fur-
thermore, in recent research by Kusunoki et al. [81],
adiponectin enhanced production of prostaglandin E2 in
synovial tissues obtained from patients with RA. All these
results may suggest that adiponectin locally produced in
joint tissues induces inflammation, which is consistent with
previous opinions that adiponectin may exhibit some pro-
inflammatory properties [82, 83]. This pro-inflammatory
action of adiponectin may be limited to selected tissues,
which would explain why, despite local changes in
adiponectin levels, serum levels of adiponectin and
adiponectin type 1 receptor did not differ between RA, OA,
or healthy subjects. If this hypothesis is correct, plasma
adiponectin levels may not reflect precisely the activity of
this AT product in particular tissues. Alternatively,
increased adiponectin production in autoimmune/chronic
inflammatory conditions might be secondary to inflamma-
tion-induced catabolic responses occurring in RA, which
are absent in inflammation associated with obesity [24, 84].
There are some reports indicating that locally abnormal
activity of adiponectin in joint tissues is not only associated
with the presence, but also determines the severity of RA.
Recent research by Ebina et al. [85] has shown that serum
adiponectin levels were higher in patients with severe RA
than in mild RA and control groups (RA was graded on the
Table 1 Effect of adipokines on arthritis and non-arthritis joint tissues
Adipokine Model Results References
Leptin Leptin deficient ob/ob mice with
antigen-induced arthritis
Less severe arthritis compared with control mice Busso et al. [58]
Reduction of T cell proliferation
Decrease in interferon-c production
Lower levels of IL-1b and TNFa mRNA in the
synovium of arthritis knees
ATDC5 mouse embryonic cells
and human articular
chondrocytes
Induction of NO-synthase expression and NO
production in articular cartilage and synovium
during treatment with leptin and interferon-c
Otero et al. [14]
Induction of NO production after leptin and IL-1
administration (mediated by PI-3 kinase, MEK-1,
and p-38 kinase pathways)
Otero et al. [59]
Adiponectin Rheumatoid synovial cells culture Strong expression of adiponectin mRNA in synovial
fibroblasts and articular adipose tissue
Ehling et al. [74]
Induction of IL-8 expression Kitahara et al. [76]
Resistin NMRI mice with intra-articularly
injected resistin
Development of arthritis with hypertrophy of the
synovial layer and pannus formation
Bokarewa et al. [34]
IL-1 interleukin, NO nitric oxide, PI-3 kinase phosphatidylinositide 3kinase, MEK-1 mitogen-activated protein kinase 1
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basis of the extent of joint destruction). It should be
underlined that the difference in adiponectin levels
between subjects with severe and mild RA did exist,
despite higher CRP levels and the use of a higher dose of
oral prednisolone by the patients with mild RA [85] (both
CRP and corticosteroids have been reported to markedly
inhibit adiponectin [86]). Similarly, there was a strong
positive correlation between serum adiponectin levels and
progression of radiographic joint destruction, including
enhanced radiographic erosions, and joint space narrowing
[87, 88] As a recent study by Klein-Wieringa et al. [89]
shows, baseline serum levels of adiponectin can predict
radiographic progression independently of the presence of
anti-cyclic citrullinated peptide antibodies and BMI. These
findings suggest that circulating adiponectin and/or adipo-
nectin produced locally by intra-articular adipocytes may
play a role in the degradation of extracellular matrix
components. These local pro-inflammatory and erosive
effects of adiponectin may result from the stimulation of
the NF-jB pathway [29] and/or osteoclastogenesis [90],
respectively. On the other hand, as suggested by Fantuzzi
[24], the catabolic state accompanied by joint destruction,
especially in large joints, may be a significant determinant
of hyperadiponectinemia.
The results presented above suggest that adiponectin may
be a target for the treatment of RA. However, adiponectin
would not be called ‘‘a controversial hormone’’ if there were
no contradictory opinions about its function. Despite many
data suggesting the pro-inflammatory action of adiponectin
in joints [29, 74, 78], it cannot be completely excluded that
high local and systemic levels of adiponectin help suppress
inflammation in patients with RA. In accordance with this
hypothesis, in collagen-induced arthritis mice and RA
synovial fibroblasts, intra-articularly injected adiponectin
significantly mitigated the severity of the arthritis and his-
topathological findings indicative of RA [91].
Unfortunately, one of the serious limitations of the
studies conducted to date is that they measured almost
exclusively total adiponectin. The ambiguous impact of
this adipokine on arthritis [29, 74, 78, 91] may, in part, be
explained by different biologic functions of various
adiponectin isoforms. The latest findings by Chedid et al.
[92] are in line with this assumption. The authors have
demonstrated that adiponectin and its globular fragment
differentially modulated the oxidative burst of primary
human phagocytes. Contrary to full-length adiponectin, its
globular form, constituting about 25 % of adiponectin in
synovial fluid, enhanced reactive oxygen species produc-
tion and phagocytic NADPH oxidase-2 expression in the
plasma membrane, with a concomitant increase in
p47(phox) phosphorylation. Interestingly, the same study
has shown that LMW adiponectin was more abundant in
synovial fluid than in serum from RA patients [92], and
these findings suggest that joint inflammation in RA may
be associated with an imbalance between different iso-
forms of adiponectin.
Although at present, the number of premises indicating
pro-inflammatory function of adiponectin in RA patients
seems to prevail over data showing its protective action,
the association between adiponectin and RA is far from
being completely understood. Because no firm conclusions
can be drawn; more research in this field is undoubtedly
required, particularly with reference to the role of adipo-
nectin isoforms.
Resistin
Although most reports concerning resistin focused on its
function in the metabolic syndrome, obesity, and IR, there is
some evidence on its role in RA and other inflammatory
diseases. The pioneering work by Schaffler et al. [71] from
2003 showed that not only adiponectin is elevated in the
synovial fluid of RA patients, but also resistin levels in the
synovium are about 10 times higher than in OA subjects.
Resistin, as it was shown by Bokarewa et al. [34], accu-
mulates locally in the inflamed joints of RA patients. Fur-
thermore, the hypothesis of pro-inflammatory resistin
function was confirmed by the development of arthritis after
resistin injection into the joints of healthy mice [34]
(Table 1). Interestingly, plasma resistin concentrations
remained low, suggesting the local intra-articular action of
this agent. Although, there are reports showing no difference
in serum resistin levels between RA patients and healthy
subjects [64], two successive studies reported a positive
correlation between circulating resistin levels and the
severity of inflammation in RA [93, 94]. Furthermore, Mi-
gita et al. [93] observed correlations between serum resistin
and CRP, ESR and TNFa in patients with RA, which is
consistent with earlier findings by Schaffler et al. [71] and a
recent report by Forsblad d’Elia et al. [94]. This study also
revealed a strong positive correlation between resistin and
IL-1 receptor antagonist, the serum level of which is ele-
vated in many rheumatic diseases [95], whereas bone min-
eral density was inversely correlated with serum resistin.
The fact that in humans resistin levels positively correlated
with coronary atherosclerosis occurrence may suggest a role
of resistin in the inflammation-based etiology of athero-
sclerosis in RA [94]. Various resistin levels in serum and
synovial fluid of RA patients [34, 64, 71, 93, 94] may be due
to or may contribute to differences in RA disease activity.
Other adipokines
The role of the remaining adipokines in the development
and progression of RA is even less understood than the role
of adiponectin, leptin, and resistin.
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Plasma levels of visfatin were found increased in
patients with RA [64]. Visfatin was evidenced to induce
chemotaxis and the production of IL-1, TNFa, IL-6, toge-
ther with costimulatory molecules by CD14C monocytes,
and to increase monocyte ability to induce alloproliferative
responses in lymphocytes [96, 97]. These features may
suggest that increased visfatin production contributes to the
pathogenesis of RA. Because visfatin is suggested to be a
part of a compensatory mechanism facilitating lipid accu-
mulation in intra-abdominal depots, it may protect the
patient against the development of rheumatoid cachexia
[64].
In a study by Senolt et al. [48], synovial fluid vaspin
levels were higher, while omentin levels were lower in RA
patients than in OA patients. Synovial fluid vaspin tended
to correlate with the activity of RA assessed by DAS28, but
not with serum CRP or a number of leukocytes in synovial
fluid. On the other hand, synovial fluid levels of omentin
correlated with serum anti-citrullinated peptide antibodies
and with IgM-rheumatoid factor [48]. Elevated serum va-
spin levels in RA patients have also been recently dem-
onstrated by Ozgen et al. [98].
In light of latest research, it seems that novel adipokines,
such as chemerin, LCN 2, and SAA3, may also play some
role in the development and progression of rheumatic
diseases. These adipose tissue proteins are partially pro-
duced by murine and human chondrocytes [53] and their
production is up-regulated by pro-inflammatory cytokines
and lipopolysaccharide [52].
Chemerin stimulates leukocyte migration to sites of
inflammation. It induces the release of C–C chemokine
ligand 2 and enhances the expression of toll-like receptor 4,
which is a well-known inhibitor of cartilage biosynthetic
activity [52]. A recent study by Eisinger et al. [99] showed
that chemerin is present in synovial fluids of RA, OA, and
psoriatic arthritis patients. Although the significance of
chemerin in innate immune system–associated joint
inflammation seems probable, its role in the pathogenesis
of rheumatic diseases is still unknown.
LCN 2 forms molecular complexes with MMP-9 and, by
protecting this MMP from autodegradation [100], may
contribute to the degeneration of cartilage. LCN 2 is highly
susceptible to upregulation by IL-1b and, therefore, arouses
interest as a potential biomarker of cartilage degeneration
in arthritic diseases.
SAA3 increases MMP-1 secretion in rabbit fibroblasts,
while the human analogue of SAA3 (A-SSA) can induce
MMP-1 and MMP-13 in human chondrocytes [101].
Significant is the finding that high concentrations of
A-SSA have been detected in the inflamed synovium of
RA and OA patients, which suggests that SAA3 is
involved in cartilage degeneration in rheumatic diseases
[101].
Systemic lupus erythematosus
SLE is a chronic, multi-system, inflammatory connective
tissue disorder with no single diagnostic marker and rela-
tively poorly understood pathogenesis. It is also an auto-
immune disease characterized by the production of auto-
reactive antibodies to various components of the cell
nucleus. It is identified on the basis of a combination of
clinical and laboratory criteria, where inflammation, vas-
culitis, immune complex deposition, and vasculopathy are
main pathological findings [102, 103]. It is noteworthy that
inflammatory processes in SLE involve not only vessel
wall, skin, and serous membranes, but also joints, kidneys,
liver, blood morphological elements, and various neuro-
psychiatric presentations [102].
Patients with SLE often fulfill the criteria of the meta-
bolic syndrome, and have accelerated atherosclerosis
development and higher prevalence of IR [104]. Taking
into consideration the significance of adipokines in induc-
ing these disorders, it seems that AT products may exhibit
a significant impact on the development and progression of
SLE. Interestingly, this disease affects mainly women. It is
in line with higher circulating levels of leptin in this gen-
der, which is caused by differences in body composition
and hormone distribution between sexes [105]. Although
the number of studies assessing the role of adipokines in
SLE is much more limited than in RA, they have shown
some relationships between adipokines and inflammatory
joint diseases.
Leptin
The results of studies assessing plasma leptin concentration
of patients with SLE are generally consistent and indicate
that high serum leptin levels might contribute to systemic
inflammation in SLE patients [62, 106, 107]. It has been
shown that serum leptin was higher in women with SLE
than in healthy controls [106], even after adjustment for
hypertension, hyperlipidemia, and diabetes [108]. Chung
et al. [109] also showed that high serum leptin levels
correlated with IR, the presence of the metabolic syn-
drome, and high levels of CRP, ESR, LDL cholesterol, and
triglycerides. Interestingly, the authors emphasized that the
difference in serum leptin levels between patients with SLE
and controls was independent of age, race, sex, and BMI.
These findings suggest that leptin production in SLE is
influenced by additional factors, which may be causatively
linked to the initiation and progression of this disorder
[109]. Despite higher serum concentrations in SLE
patients, the association between leptin levels and disease
activity (stratified according to the MEX-SLEDAI scores)
has not been evidenced [110]. Unexpectedly, no differ-
ences in leptin levels between patients with SLE and
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healthy subjects were found in the research by Wislowska
et al. [111], who also observed lower serum leptin levels in
SLE patients with neurological disorders and arthritis than
in individuals free from them.
Interestingly, Ha¨rle et al. [112] found the presence of an
inverse correlation between serum levels of leptin and
androstenedione in both SLE and RA patients. This finding,
suggesting that leptin inhibits androstenedione secretion,
may partially explain hypoandrogenism, which is fre-
quently observed in patients with chronic inflammatory
diseases [112].
Adiponectin
It has been demonstrated that the risk of IR in patients with
SLE is higher compared with age-matched healthy controls
[113]. Regarding the fact that adiponectin enhances insulin
sensitivity, this adipokine may be involved in the patho-
genesis of SLE and the development of its complications.
In a report by Sada et al. [108], serum levels of adiponectin
were significantly elevated in SLE without IR compared
with healthy controls, and lower levels of adiponectin were
noted in SLE patients with IR compared to SLE subjects
without IR. Although adiponectin was negatively corre-
lated with IR in SLE subjects, serum levels of this adipo-
kine in SLE patients with reduced insulin sensitivity
exceeded those observed in healthy subjects. Though the
authors were reluctant to draw any definite conclusion, they
speculated that the stimulating effect of adiponectin on
insulin sensitivity might be impaired in some patients with
SLE. Increased plasma concentrations of adiponectin in
patients with SLE were also observed by Chung et al.
[109]. Interestingly, despite this fact, these authors found
the negative correlation between plasma adiponectin and
BMI, presence of metabolic syndrome, systolic blood
pressure, and dyslipidemia in patients suffering from this
disorder. In the study by Rovin et al. [110], the authors
showed that serum adiponectin levels are higher in patients
with renal SLE than in healthy controls and in patients with
non-renal SLE. Furthermore, during renal SLE flare, urine
adiponectin loss was markedly increased. Noteworthy is
the fact that HMW adiponectin isoform has recently been
found in urine of patients with active lupus nephritis, but
not in urine of healthy individuals, and its content corre-
lated with lupus severity [30]. Because HMW isoform has
been demonstrated to induce IL-8 and MCP-1 production,
higher amounts of this isoform may result in pro-inflam-
matory properties of adiponectin in this group of patients.
Resistin
There is no agreement as for concentrations and function of
resistin in SLE, because of a limited number of studies and
their inconsistent results. Only in one report, the authors
found the existence of a relationship between serum resi-
stin levels and the severity of inflammation, bone mass
density (BMD), and renal function in SLE patients [114].
Serum resistin levels correlated also with low HDL cho-
lesterol and high IgG levels, as well as with elevated levels
of pro-inflammatory cytokines—IL-1b, IL-6, and TNFa
and soluble IL-6 receptor in serum. The association
between resistin, ESR, and complement component 3 (C3)
levels, observed in this study, may reflect disease activity
[114]. In other studies, correlation between SLE occur-
rence and serum resistin concentrations was not found
[109, 115, 116]. However, in one of these studies [109], a
weak association between resistin and ESR was revealed.
Due to a small number of studies and their limitations, at
present it is too vague to make any firm conclusions con-
cerning the involvement of resistin in SLE.
Other connective tissue disorders
Sjo¨gren’s syndrome
Sjo¨gren’s syndrome (SS) is an autoimmune disorder which
is characterized by chronic dysfunction and destruction of
salivary and lacrimal glands, leading to persistent dryness
of the mucosa [117]. Destruction of the salivary glands is
accompanied by the development of adipose tissue and
fibrotic tissue, which may suggest the involvement of
adipocytes in the pathogenesis of this disorder. There are
only a few studies investigating adipokine levels/produc-
tion in patients with SS. Toussirot et al. [118] observed a
marked increase in circulating adiponectin concentration in
a small group of patients with SS. Katsiougiannis et al.
[119] investigated the expression of adiponectin in minor
salivary gland biopsy specimens obtained from patients
with SS and controls. The authors observed increased
constitutive secretion of adiponectin by salivary gland
epithelial cells from patients with SS compared with con-
trols, but did not find any changes in the production of
adiponectin by adipocytes. Another study [120] revealed
elevated saliva resitin levels, despite unaltered plasma
levels of this adipokine, as compared with healthy controls,
which corresponded to the intensity of lymphocytic
inflammation in salivary glands [120]. It seems that locally
produced adiponectin exerts anti-proliferative and anti-
apoptotic effects on salivary gland epithelial cells through
the activation of AMP-activated protein kinase [121].
These findings indicate that adiponectin and resistin may
locally regulate immune processes, regardless of their
metabolic functions. They also suggest that plasma
adipokine concentrations seem not to be as sensitive indi-
cators of local inflammatory processes as their saliva
levels.
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Ankylosing spondylitis
Ankylosing spondylitis (AS) is a chronic inflammatory
disease with 0.2–0.9 % prevalence among the population
[122]. It mainly affects the axial skeleton, but it is also a
risk factor for cardiovascular disease. Serum concentration
of adiponectin has been found to be unaffected in AS
patients compared to controls [123]. Some [122, 123], but
not other, [124] authors showed a significant decrease in
serum leptin concentration in patients with AS and a
reduction in adipose tissue mass [122]. Sari et al. [122]
even speculated that decreased leptin levels might be used
as a marker of disease activity in AS. However, taking into
account the limited number of studies investigating serum
levels of leptin, adiponectin, and other adipokines in AS
and their inconsistent results, as well as the fact that no
study has assessed synovial fluid adipokine concentration
in this disorder, the role of adipose tissue hormones in the
development and progression of AS requires better
understanding.
Systemic sclerosis
Very little is known about relevance of adipokines in the
pathogenesis of systemic sclerosis. Individuals suffering
from this disorder had lower serum leptin levels compared
with healthy subjects [125]. However, taking into consid-
eration the fact that the participants of this study tended to
have decreased body mass, while leptin levels correlated
with BMI, low leptin levels may have reflected body
weight loss rather than inflammatory process directly
responsible for the development of this disorder.
Serum adiponectin levels and adiponectin mRNA levels
in skin tissues were reduced in patients with diffuse cu-
taneus scleroderma, having higher total skin thickness score
and higher incidence of pulmonary fibrosis. Although these
findings suggest that serum adiponectin levels may be a
useful biomarker for fibrotic condition in systemic sclerosis,
further studies are required to confirm this hypothesis [126].
Adipokines and treatment of connective tissue diseases
The issue of whether anti-TNFa therapy affects leptin,
adiponectin, and resistin concentrations in patients with RA
have been investigated in several recent studies [127–132].
Because the production of some adipokines is regulated by
TNFa, IL-1, and other pro-inflammatory cytokines, bio-
logical treatment of RA should at first glance change
adipokine production and release. Unfortunately, in the
case of leptin, all conducted studies showed that anti-TNFa
therapy has either limited impact [127] or even does not
[128, 129] change its plasma concentration. Futhermore,
Gonzalez-Gay et al. [130] showed that serum leptin levels
in infliximab-treated RA patients did not correlate with the
parameters determining disease activity and the severity of
inflammation. Although in the said study circulating leptin
levels during anti-TNFa therapy correlated with the content
of AT, a similar correlation was observed also in non-RA
control subjects. Interestingly, in an earlier study of the
same research group, the authors observed a rapid reduc-
tion of serum resistin levels in RA patients treated with
anti-TNFa therapy, which may support a potential role of
this adipokine in the inflammatory cascade in RA [131].
Studies assessing adiponectin levels during anti-TNFa
therapy in RA patients provided contrasting results. Ha¨r-
leet al. [129] did not find any changes in serum adiponectin
levels during anti-TNFa therapy with adalimumab, while
Nagashima et al. [132] observed increased plasma levels of
this protein after treatment with etanercept and infliximab.
The latter results may be explained by a direct effect of
TNFa blockade, because both TNFa and adiponectin
reciprocally inhibit the production of each other [132]. As
high TNFa and resistin as well as low adiponectin levels
are associated with increased cardiovascular risk [133],
pharmacological blockage of TNFa, apart from exhibiting
anti-inflammatory effect, may lead to a reduction in car-
diovascular morbidity and mortality. Unfortunately, owing
to a very limited number of studies assessing the rela-
tionship between anti-cytokine agents and adipokine pro-
duction, this hypothesis is a bit speculative and needs to be
verified in future studies.
Therapeutic perspectives
Since their discovery, most researchers have paid attention
to therapeutic application of adipokines, their analogs and
derivatives in the treatment of metabolic disorders. The
results of many studies described in this review indicate
that the modification of the adipokine network should be
considered as one of future treatment options for connec-
tive tissue diseases.
The involvement of leptin in the pathogenesis of
inflammatory and autoimmune diseases allows us to
believe that prevention of leptin-induced inflammation may
bring benefits to both RA and SLE subjects. This may be
obtained using high-affinity leptin-binding molecules
(analogously to the soluble TNFa receptors used to treat
RA) or by blocking the leptin receptor with monoclonal
humanized antibodies or mutant leptins, which are able to
bind to this receptor without activating it [7]. Another
challenging possibility of leptin modulation is the use of
epigenetic therapy or targeted gene therapy. In line with
this possibility, epigenetic therapy produced an impact on
leptin expression in normal chondrocytes, while targeted
gene therapy using small interference RNA transferred
with liposomes dramatically inhibited MMP-13 expression
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Leptin : : ESR higher in moderate disease activity
RA group compared to low activity group
(P \ 0.001)
Seven et al. [63]
: – Otero et al. [64]
: – Targonska-Stepniak et al. [65]
: – Disease activity evaluated by DAS 28, ESR,
and the number of tender joints
Bokarewa et al. [66]
0 – No adjustment for BMI Anders et al. [67]
0 – Popa et al. [70]
Adiponectin – : Stimulation of IL-6 and pro-MMP-1
production in synovial fibroblasts
Tang et al. [29]
0 : Compared to OA patients Schaffler et al. [71]
: : Compared to OA patients Senolt et al. [73]
0 : Compared to OA patients Tan et al. [79]
: – Serum adiponectin levels were higher
in patients with severe RA than in
mild RA and control groups
Ebina et al. [85]
Resistin 0 : Positive correlation between synovial
resistin levels and severity of inflammation
defined by intra-articular white blood cell
count and IL-6 levels
Bokarewa et al. [34]
: : Positive correlation between serum resistin
and: (1) CRP, (2) DAS 28
Senolt et al. [136]
– : Compared to OA patients
Positive correlations between synovial resistin
levels and (1) ESR, (2) CRP
Schaffler et al. [71]
: – Positive correlations between serum resistin
and (1) CRP, (2) ESR, (3) TNFa
Migita et al. [93]
0 – Positive correlation between resistin and IL-1Ra Forsblad d’Elia et al. [94]
Systemic lupis erythematosus (SLE)
Leptin : – Garcia-Gonzalez et al. [106]
: – Sada et al. [108]
: – Positive correlation between high
serum leptin levels and (1) IR,
(2) the presence of the metabolic syndrome,
(3) CRP, (4) ESR, (5) LDL cholesterol,
(6) triglycerides
Chung et al. [109]
; – Signifcantly lower serum leptin levels in
SLE patients with arthritis and central
nervous system (CNS) involvement in
comparison with SLE patients without
arthritis and CNS involvement
Wislowska et al. [111]
Adiponectin : – Lower levels of adiponectin SLE patients with
IR compared to SLE subjects without IR
Sada et al. [108]
: – Negative correlation between plasma
adiponectin and (1) BMI, (2) presence of
metabolic syndrome, (3) systolic blood
pressure, (4) dyslipidemia
Chung et al. [109]
: – Serum adiponectin levels higher in patients
with renal SLE than in healthy controls
and in patients with non-renal SLE
Rovin et al. [110]
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in osteoarthritic chondrocytes [134]. Whichever strategy is
chosen, it should not modify the influence of leptin on food
intake in order to avoid the development of hyperphagia
and obesity. Because of unresolved doubts as to the role in
the regulation of inflammatory processes, more contro-
versial remains the question of the use of drugs affecting
the adiponectin system. Moreover, owing to the existence
of various forms of adiponectin, their actions may differ
markedly, and therefore, using adiponectin-directed agents
in RA or SLE patients requires further study.
A more promising target for the development of novel
therapeutics for the treatment of inflammatory diseases
seems to be visfatin. Neutralization of visfatin by its
inhibitor (APO866) effectively reduced arthritis severity in
mice with comparable activity to etanercept, and decreased
pro-inflammatory cytokine (IL-1b and IL-6) secretion in
affected joints [135]. Another interesting direction for a
new treatment option for connective tissue disease is
inhibiting the synthesis, release, and action of resistin by
anti-resistin agents.
It should be remembered that the mechanism of action
of each adipokine seems to consist not only of its direct
effect, but also of its indirect effect resulting in the mod-
ulation of other adipose tissue protein systems. The pres-
ence of numerous adipokine systems and the possibility of
numerous interactions between them result in precise
response to energetic and immunological balance changes
and consequently in the precise regulation of organism
homeostasis. This fact, although favorable in normal con-
ditions, may hamper the efficacy of the treatment of
immunological disorders because the pharmacological
manipulation of the activity of a single system alters the
activity of other systems, thus neutralizing the therapeutic
effect achieved. This may justify the use of agents affecting
more than one adipokine system in the treatment of con-
nective tissue disorders.
Discussion
Most of the data presented by different research groups
showed increased levels of leptin, adiponectin, and resistin
in plasma and synovial fluid in RA and SLE (Table 2).
Nevertheless, despite efforts, it still remains obscure whe-
ther the observed disturbances in various adipokine sys-
tems in subjects with connective tissue diseases contribute
to their development or only mirror the presence or activity
of inflammatory process, which itself is induced by other
pro-inflammatory factors. It remains unanswered why
some adipokines, particularly adiponectin, produce pro- or
anti-inflammatory effects in connective tissue diseases and
why clinical studies assessing plasma and synovial fluid
concentrations of various adipokines provided contrasting
results. Plasma levels of adipokines might tell us too little
about their role in connective tissue disorders due to the
fact that adipokine secretion depends on numerous factors,
such as different anatomic distribution of adipose tissue,
adipocyte size, and hormonal regulation. Moreover, dif-
ferent forms of the same protein might produce different
effects on inflammation. Adipokine effects on synovial
tissues might differ from their known metabolic or car-
diovascular effects, which implies that some re-appraisal of
adipokine role may need to take place. Because data
regarding seemingly well-known adipokines tend to be
ambiguous, it appears that a better understanding of the
role of ‘‘new adipokines’’ (visfatin, acylation-stimulating
protein, vaspin, apelin, fasting-induced adipose factor,







Resistin 0 – Weak positive correlation between
resistin and ESR
Chung et al. [109]
0 – Positive correlation between resistin
and (1) creatinine, (2) IgG, (3) IL-1b, IL-6,
and TNFa and soluble IL-6 receptor in serum
Negative correlation between resistin
and (1) GFR, (2) HDL cholesterol,
(3) BMD, (4) complement levels
Almehed et al. [114]
0 – Vadacca et al. [115]
0 – De Sanctis et al. [116]
‘‘:’’—elevated concentration of adipokine, ‘‘;’’—decreased concentration of adipokine, ‘‘0’’—no differences in concentration between patients
and controls, ‘‘–’’—data not assessed, OA osteoarthritis, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS-28 disease activity
score, TNFa tumor necrosis factor a, IR insulin resistance, GFR glomerular filtration rate, BMI body mass index, BMD bone mass density,
pro-MMP-1 pro-matrix metalloproteinase-1, IL-6 interleukin 6, IL-1Ra interleukin 1 receptor antagonist
a Patients versus healthy controls unless other control group is stated in comments
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amyloid A3) and their cooperation with ‘‘old adipokines’’
could throw light on the pathogenesis of inflammatory
processes.
Establishing the exact position of adipose tissue proteins
in the pathogenesis of connective tissue diseases, apart from
pathophysiological implications, arouse deep interest
because adipokine systems may in the future become
potential targets for new effective and safe pharmacological
agents for the treatment of RA, SLE, and other autoimmune
disorders. New developments concerning AT hormonal
function has not provided definite answers to numerous
questions and paradoxically even raised additional queries.
Therefore, further studies are required to establish the
proper role of adipokines in connective tissue diseases.
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